Bottom line
BBH vs RYOIX: the short answer
BBH (VanEck Biotech ETF) and RYOIX (Biotechnology Fund) share a meaningful slice of their top holdings — about 64% by weight.
But RYOIX is far broader, holding 74 positions to 25 for BBH, so beyond the top names it adds exposure BBH doesn't have.
BBH is cheaper at 0.35% vs 1.38% — a difference of $103 a year per $10,000 invested.
Over five years, RYOIX returned +4.0% a year vs +2.7% for BBH.
Updated Nov 19, 2026
BBH vs RYOIX side by side
| BBH | RYOIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | VanEck | Guggenheim |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 1.38% |
| Annual cost per $10k | $35 | $138 |
| 10-yr cost on $10k (prospectus) | $443 | $1,709 |
| Max front load | None | — |
| 12b-1 fee | — | 0% |
| 1-yr return | +21.2% | +30.7% |
| 5-yr return (annualized) | +2.7% | +4.0% |
| 10-yr return (annualized) | +4.5% | +5.9% |
| Best quarter | +27.6% | +28.3% |
| Worst quarter | −18.2% | −22.5% |
| Net assets (fund) | $395.6M | $136.8M |
| Number of holdings | 25 | 74 |
| Portfolio turnover | 19% | 75% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | BBH | RYOIX | Difference |
|---|---|---|---|
| 2025 | +21.2% | +30.7% | −9.6% |
| 2024 | −4.4% | −0.7% | −3.6% |
| 2023 | +3.9% | +6.1% | −2.2% |
| 2022 | −15.1% | −13.1% | −2.1% |
| 2021 | +11.8% | +1.8% | +10.0% |
| 2020 | +22.1% | +22.1% | −0.0% |
| 2019 | +25.8% | +25.0% | +0.7% |
| 2018 | −10.2% | −9.0% | −1.2% |
| 2017 | +16.6% | +29.7% | −13.1% |
| 2016 | −15.0% | −19.5% | +4.5% |
Source: Fund prospectus bar charts
Holdings overlap
16 of BBH's top 25 holdings also appear in RYOIX's top 25.
| Holding | BBH | RYOIX |
|---|---|---|
| Amgen Inc | 15.25% | 5.05% |
| Gilead Sciences Inc | 12.79% | 4.49% |
| Vertex Pharmaceuticals Inc | 9.10% | 4.32% |
| Regeneron Pharmaceuticals Inc | 6.21% | 2.93% |
| Revolution Medicines Inc | 5.27% | 2.48% |
| Argenx SE | 4.97% | 1.48% |
| Natera Inc | 4.92% | 2.12% |
| Alnylam Pharmaceuticals Inc | 3.83% | 2.36% |
| Biogen Inc | 3.63% | 2.13% |
| Moderna Inc | 3.36% | 2.15% |
| Illumina Inc | 3.17% | 1.94% |
| United Therapeutics Corp | 2.83% | 1.72% |
| BeOne Medicines Ltd | 2.81% | 2.17% |
| Insmed Inc | 2.67% | 1.79% |
| Incyte Corp | 2.49% | 1.62% |
Source: SEC Form N-PORT
BBH top 10
- Amgen Inc — 15.25%
- Gilead Sciences Inc — 12.79%
- Vertex Pharmaceuticals Inc — 9.10%
- Regeneron Pharmaceuticals Inc — 6.21%
- Revolution Medicines Inc — 5.27%
- Argenx SE — 4.97%
- Natera Inc — 4.92%
- IQVIA Holdings Inc — 4.31%
- Alnylam Pharmaceuticals Inc — 3.83%
- Biogen Inc — 3.63%
RYOIX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
FAQ
What is the difference between BBH and RYOIX?
Which is cheaper, BBH or RYOIX?
Should I own both BBH and RYOIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.